Fig. 2.
The relapsed disease after targeted therapy with pleural and lung metastases (A, B). Hyperprogressive disease after two treatment cycles of PD-1 inhibitor sintilimab monotherapy (C, D)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.